MedTrace Logo

Study of DWP450 in Japanese Subjects With Glabellar Lines

NCT07783763 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-08-26

No results posted yet for this study

Summary

Study to Evaluate the Efficacy and Safety of DWP450 in Japanese Subjects with Moderate to Severe Glabellar Lines

Conditions

  • Glabellar Lines

Interventions

DRUG

DWP450 20 U

Clostridium botulinum Toxin type A

DRUG

0.9% Saline Solution 0.5 mL

Normal Saline 0.5 mL

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-31
Primary Completion
2028-05-31
Completion
2028-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07783763 on ClinicalTrials.gov